Shire (SHP) Stock Rating Reaffirmed by Shore Capital
Shore Capital reissued their buy rating on shares of Shire (LON:SHP) in a research note released on Monday. The brokerage currently has a GBX 3,607 ($51.65) price target on the biopharmaceutical company’s stock.
A number of other analysts also recently commented on SHP. JPMorgan Chase downgraded shares of Shire to a neutral rating and cut their price objective for the company from GBX 5,000 ($71.59) to GBX 3,600 ($51.55) in a report on Tuesday, February 20th. BNP Paribas restated an outperform rating and set a GBX 4,700 ($67.30) price target on shares of Shire in a report on Thursday, March 22nd. Morgan Stanley lowered their price objective on shares of Shire from GBX 5,700 ($81.62) to GBX 4,700 ($67.30) and set an overweight rating for the company in a research report on Monday, March 19th. Citigroup reaffirmed a buy rating and set a GBX 5,500 ($78.75) price objective on shares of Shire in a research report on Friday, January 5th. Finally, Goldman Sachs reissued a conviction-buy rating and issued a GBX 4,600 ($65.86) price target on shares of Shire in a research report on Monday, March 26th. Five analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. Shire presently has a consensus rating of Buy and a consensus target price of GBX 4,550.80 ($65.16).
SHP stock opened at GBX 3,617 ($51.79) on Monday. Shire has a 52-week low of GBX 2,940.50 ($42.10) and a 52-week high of GBX 5,021 ($71.89).
TRADEMARK VIOLATION WARNING: “Shire (SHP) Stock Rating Reaffirmed by Shore Capital” was published by Daily Political and is the property of of Daily Political. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.dailypolitical.com/2018/04/17/shire-shp-stock-rating-reaffirmed-by-shore-capital.html.
Shire Company Profile
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells specialist medicines for people with rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.